News
Eli Lilly and United Health Group partner on pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19.
Eli Lilly and Company and United Health Group announced a partnership to conduct a pragmatic study of (LY-CoV555) in high-risk, COVID-19 infected individuals. Bamlanivimab recently received Emergency Use Authorization (EUA) by the FDA for the treatment of mild to moderate COVID-19 patients who are at high risk for progressing to severe COVID-19 and/or hospitalization.
The trial will evaluate the efficacy and safety of bamlanivimab versus a propensity-matched control in individuals that meet the EUA criteria. The study will identify and treat a large, diverse population of high-risk individuals for COVID-19 with bamlanivimab under real-world conditions with a goal of reducing the severity of illness and hospitalizations. It will draw upon both United Health Group's United Healthcare health benefits business as well as its Optum health services business to detect and treat high-risk symptomatic patients who test positive for COVID-19, including daily symptom tracking, in-home SARS-CoV-2 testing and in-home infusion services.
Delivering bamlanivimab to patients through home infusions allows them to stay quarantined and at home, minimizing the potential spread of COVID-19.
Condition: Coronavirus/COVID-19 Infection
Type: drug